華大基因:研製不明原因兒童急性肝炎篩查聯合方案
華大基因昨日宣布,鑑於最近新發現的不明原因兒童急性肝炎流行趨勢,以及不明原因肝炎的潛在病因腺病毒,尤其是F41型本身廣泛存在,公司就此提供全面的檢測篩查方案。
華大基因表示,採用腺病毒及腺病毒F41型核酸檢測試劑盒,一個小時內可完成快速篩查,並對篩查陰性的臨床病例可進一步採用PMseq病原高通量測序探究潛在新病原。聯合方案或可大幅提升對不明原因兒童急性肝炎的病原檢測能力,幫助診斷不明原因兒童急性肝炎感染。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.